Salivary duct carcinoma (cribriform salivary carcinoma of excretory ducts) a clinicopathologic and immunohistochemical study of 12 cases

Abstract

Salivary duct carcinoma (cribriform salivary carcinoma of the excretory ducts [CSCED]) is an uncommon malignant tumor which occurs predominantly in men (83% in this series; mean age, 61 years) and most often in the parotid gland (92% in this series). The outcome is unfavorable for most patients; of 11 of 12 patients with follow-up, 45% had local recurrence, 54% had distant metastasis, and 45% were dead of disease within 10 years of diagnosis (mean, 3 years). Metastases to lymph nodes were common (72%). Immunohistochemical studies on paraffin-embedded tissue revealed that most tumors reacted with antibodies known to mark adenocarcinoma: B72.3 (11 of 11) and Lewis Y (ten of ten). High and low molecular weight cytokeratins were present in most tumors (nine of ten and seven of nine cases, respectively), supporting the concept that these adenocarcinomas were of ductal origin. Parotid ducts adjacent to CSCED expressed B72.3 in six of nine cases studied, but parotid ducts from normal tissue (adjacent to benign mixed tumors or enlarged periparotid lymph nodes) rarely expressed this marker (one of 17 cases). The detection of B72.3 diffusely in parotid ducts, especially those with atypia, may imply the presence of malignant tumor nearby, which could be useful in evaluating limited tissue from the parotid. However, further studies are necessary to confirm the significance of this finding.

Low-Grade Salivary Duct Carcinoma or Low-Grade Intraductal Carcinoma? Review of the Literature

“…LG-SDC and conventional SDC are composed of neoplastic cells with ductal phenotype and varying degree of apocrine differentiation and AR expression [1,6,14,31,41] but exhibit significant clinicopathologic differences including the expression of S100 protein, with 84 % of LG-SDCs positive for S100 protein. In contrast, the data regarding S100 protein expression in conventional SDC is more controversial with Lewis et al [30] reporting expression in only 4 % while Brandwein et al [42] reported reaction in 100 % of cases. The presence of at least focal LG-SDC has not been described in any study of conventional SDC.…”

Salivary Gland Neoplasia: A Review for the Practicing Pathologist

“…This may represent precursor ductal carcinoma in situ or cancerization of native preexisting excretory ducts. Prognostically favorable pathologic observations include an intraductal component comprising greater than 90% of the tumor and smaller tumor size of less than 2-3 centimeters (95,96). Discrimination from the rarely reported purely intraductal high grade carcinoma may require immunohistochemistry to clarify (78,79).…”

“…Brandwein and colleagues' review of 58 cases demonstrated 55% of patients dead of disease within a mean of 29 months (96). Therefore, these cancers are treated aggressively with complete excision, radical neck dissection and postoperative radiation therapy.…”

Submandibular Gland Adenocarcinoma of Intercalated Duct Origin in Smgb-Tag Mice

“…1985) and Wharton's duct (Dardick 1996b), but are more often a component of salivary duct carcinoma (Brandwein et al, 1990;Garland et al, 1984;Hui et al, 1986). In situ carcinoma is also part of the cytologic and histologic spectrum of carcinoma ex pleomorphic adenoma (Brandwein et al, 1996;LiVolsi and Perzin, 1977;Yamamoto et al, 1996Yamamoto et al, , 1998.…”